Research information only — not medical advice. Full disclaimer
Peptide Library

Peptide profile

Kidney Animal data

SS-31 (Elamipretide)

Mitochondrial peptide for renal protection

Compare SS-31 (Elamipretide) with other peptides →

Summary

Mitochondrial-targeted peptide for kidney & metabolic protection.

A tiny protein that helps protect your kidneys and your body's powerhouses.

Typical dose
5-10mg Daily
Route
Subcutaneous
Cycle length
30-60 days
Evidence
Animal data

Mechanism

How it works

SS-31 acts like a repair kit for kidney cell power plants — it fixes damaged mitochondria that would otherwise fail and cause scarring.

SS-31 targets cardiolipin in mitochondrial inner membranes, reducing ROS and preserving renal tubular function in models of kidney disease.

SS-31 targets cardiolipin in mitochondrial inner membranes, reducing ROS and preserving renal tubular function in models of kidney disease.

Reported in research

Benefits

  • Reduces renal oxidative stress
  • Protects against diabetic nephropathy
  • Improves mitochondrial function in kidneys
  • Reduces renal fibrosis
  • Helps lower stress and damage inside your kidneys
  • Helps guard kidneys from harm caused by diabetes
  • Helps your kidney cells' tiny power plants work better
  • Helps stop your kidneys from getting stiff and scarred

Context, not a prescription

Dosing

Typical range
5-10mg Daily (Subcutaneous)
Cycle length
30-60 days

Safety

Side effects & contraindications

Possible side effects

  • Injection site pain
  • Mild nausea
  • Temporary fatigue
  • Headache
  • Dizziness

Contraindications

  • Pregnancy or breastfeeding
  • Severe mitochondrial disorders (clinical use only)

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Less kidney scarring, better kidney health, and less protein leaking into your pee.

How it works

Think of SS-31 like a repair kit for the kidney cells' power plants. It fixes broken ones before they fail and cause scars.

It goes straight to the tiny power plants in your kidneys. There it protects them from damage.

What to expect

Kidney protection over 4-8 weeks.

  • Weeks 2-4: Less stress and damage inside the kidneys.
  • Weeks 4-6: The tiny cell power plants work better.
  • Weeks 6-8: Less stiffness and scarring in the kidneys.

Good to know

  • Start with a smaller amount (5mg)
  • Take breaks between cycles

Staying safe

  • Soreness where you get the shot
  • A little upset tummy
  • Feeling tired for a short time

Avoid if you have:

  • People who are pregnant or breastfeeding
  • People with serious power-plant cell problems (only with a doctor)

Overview

Reduced renal fibrosis, improved kidney function markers, less proteinuria.

How it works

SS-31 acts like a repair kit for kidney cell power plants — it fixes damaged mitochondria that would otherwise fail and cause scarring.

Selectively accumulates in kidney mitochondria, protecting cardiolipin from oxidative damage.

Onset & timeline

Renal protection over 4-8 weeks.

  • Weeks 2-4: Reduced oxidative stress markers.
  • Weeks 4-6: Improved mitochondrial function.
  • Weeks 6-8: Reduced renal fibrosis.

Getting the most from it

  • Start with lower dose (5mg)
  • Cycle with breaks

Common side effects

  • Injection site pain
  • Mild nausea
  • Temporary fatigue

Mechanism of action

SS-31 targets cardiolipin in mitochondrial inner membranes, reducing ROS and preserving renal tubular function in models of kidney disease.

Selectively accumulates in kidney mitochondria, protecting cardiolipin from oxidative damage.

Pharmacodynamics

Renal protection over 4-8 weeks.

Reduced renal fibrosis, improved kidney function markers, less proteinuria.

Timeline

  • Weeks 2-4: Reduced oxidative stress markers.
  • Weeks 4-6: Improved mitochondrial function.
  • Weeks 6-8: Reduced renal fibrosis.

Comparisons

  • SS-31 — effectiveness Emerging, safety Good, cost $$$, Medium to use
  • ARA-290 — effectiveness Emerging, safety Good, cost $$$, Medium to use

Adverse effects

Common:

  • Injection site pain
  • Mild nausea
  • Temporary fatigue

Rare:

  • Headache
  • Dizziness

Contraindications & risk mitigation

Contraindicated in:

  • Pregnancy or breastfeeding
  • Severe mitochondrial disorders (clinical use only)
  • Start with lower dose (5mg)
  • Cycle with breaks

Qué hace

Menos cicatrices en los riñones, mejor salud renal y menos proteínas que se filtran en tu orina.

Cómo funciona

Piensa en SS-31 como un kit de reparación para las centrales de energía de las células renales. Repara las averiadas antes de que fallen y causen cicatrices.

Va directamente a las pequeñas centrales de energía de tus riñones. Allí las protege del daño.

Qué esperar

Protección renal en 4-8 semanas.

  • Semanas 2-4: Menos estrés y daño dentro de los riñones.
  • Semanas 4-6: Las pequeñas centrales de energía celular funcionan mejor.
  • Semanas 6-8: Menos rigidez y cicatrices en los riñones.

Bueno saber

  • Comenzar con una cantidad más pequeña (5 mg)
  • Tomar descansos entre los ciclos

Manteniéndose seguro

  • Molestias en el lugar de la inyección
  • Un poco de malestar estomacal
  • Sentirse cansado por un corto tiempo

Evitar si tienes:

  • Personas que están embarazadas o en período de lactancia
  • Personas con problemas graves en las centrales de energía celular (solo con un médico)

Descripción general

Reducción de la fibrosis renal, mejora de los marcadores de función renal y menor proteinuria.

Cómo funciona

SS-31 actúa como un kit de reparación para las centrales de energía de las células renales: repara las mitocondrias dañadas que de otro modo fallarían y causarían cicatrices.

Se acumula selectivamente en las mitocondrias renales, protegiendo la cardiolipina del daño oxidativo.

Inicio y cronología

Protección renal en 4-8 semanas.

  • Semanas 2-4: Reducción de marcadores de estrés oxidativo.
  • Semanas 4-6: Mejora de la función mitocondrial.
  • Semanas 6-8: Reducción de la fibrosis renal.

Cómo aprovecharlo al máximo

  • Comenzar con dosis más baja (5 mg)
  • Realizar ciclos con descansos

Efectos secundarios comunes

  • Dolor en el sitio de inyección
  • Náuseas leves
  • Fatiga temporal

Mecanismo de acción

SS-31 se dirige a la cardiolipina en las membranas mitocondriales internas, reduciendo ROS y preservando la función tubular renal en modelos de enfermedad renal.

Se acumula selectivamente en las mitocondrias renales, protegiendo la cardiolipina del daño oxidativo.

Farmacodinamia

Protección renal en 4-8 semanas.

Reducción de la fibrosis renal, mejora de los marcadores de función renal y menor proteinuria.

Cronología

  • Semanas 2-4: Reducción de marcadores de estrés oxidativo.
  • Semanas 4-6: Mejora de la función mitocondrial.
  • Semanas 6-8: Reducción de la fibrosis renal.

Comparaciones

  • SS-31 — efectividad Emergente, seguridad Buena, costo $$$, Media de usar
  • ARA-290 — efectividad Emergente, seguridad Buena, costo $$$, Media de usar

Efectos adversos

Comunes:

  • Dolor en el sitio de inyección
  • Náuseas leves
  • Fatiga temporal

Raros:

  • Dolor de cabeza
  • Mareos

Contraindicaciones y mitigación de riesgos

Contraindicado en:

  • Embarazo o lactancia
  • Trastornos mitocondriales graves (solo uso clínico)
  • Comenzar con dosis más baja (5 mg)
  • Realizar ciclos con descansos

Reference data

Specifications

Route
Subcutaneous
Cycle length
30-60 days

FAQ

Common questions

Is SS-31 effective for chronic kidney disease?

Animal studies show benefit in diabetic nephropathy and toxin-induced injury; human trials ongoing.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for SS-31 (Elamipretide) is rated as Animal data. Research is based primarily on animal models.

  1. 1. SS-31 in kidney disease (2014) — DOI:10.1681/ASN.2013040419
  2. 2. Mitochondrial peptides in nephrology (2017) — DOI:10.1016/j.kint.2017.03.034
  3. 3. SS-31 in kidney disease (2014)
  4. 4. Mitochondrial peptides in nephrology (2017)